RxDoctor Payments Data

Brenda Karagozian, MD

Family Medicine · Flint, TXNPI 1700383387

Payments from drug & device makers

$5,325in general payments, 2019–2025

Across 275 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$821
  • Lilly USA, LLC$713
  • Pfizer$664
  • Bayer$608
  • AstraZeneca$526
  • GSK$387
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$5,325100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,325 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$65,854
Medicare patients
126
Services billed
856

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide32$56,516
JardianceEmpagliflozin30$36,937
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$26,210
EliquisApixaban24$20,625
MounjaroTirzepatide15$17,086
Rosuvastatin Calcium176$2,624
Levothyroxine Sodium158$1,486
Atorvastatin Calcium180$1,363
Ventolin HfaAlbuterol Sulfate22$1,331
Omeprazole85$1,120
Albuterol Sulfate HfaAlbuterol Sulfate48$1,013
Pantoprazole Sodium72$874
Bupropion XlBupropion Hcl35$833
Ezetimibe43$822
Lisinopril121$757

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$821$56,51632 claims
Boehringer IngelheimJardiance$308$36,93730 claims
GSKTrelegy Ellipta$387$26,21038 claims
PfizerEliquis$664$20,62524 claims
Lilly USA, LLCMounjaro$713$17,08615 claims
AbbVieSynthroid$372$51913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Flint

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →